<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546022</url>
  </required_header>
  <id_info>
    <org_study_id>GSP-001</org_study_id>
    <nct_id>NCT04546022</nct_id>
  </id_info>
  <brief_title>GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver</brief_title>
  <acronym>GSP</acronym>
  <official_title>GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Defense Medical Center, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardinal Tien Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Defense Medical Center, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the galactose single point (GSP) cutoff values to&#xD;
      discriminate subjects with different hepatic function. The secondary objective is to analyze&#xD;
      the correlations between GSP and other hepatic function assessment methods among this trial&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, including&#xD;
      the potential for progression to nonalcoholic steatohepatitis (NASH), followed by fibrosis&#xD;
      and ultimately cirrhosis. The gold standard to evaluate fibrosis in patients with NAFLD is&#xD;
      liver biopsy. The investigators aimed to evaluate the clinical utility of using the galactose&#xD;
      single point (GSP) test which recommended by the US FDA to quantitatively measure liver&#xD;
      function in patients with NAFLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2007</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 12, 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentration of galactose</measure>
    <time_frame>Sixty minutes</time_frame>
    <description>To determine the GSP cutoff values based on data obtained from this trial to discriminate subjects with different hepatic function</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Galactose Single Point (GSP), Residual Liver Function</condition>
  <arm_group>
    <arm_group_label>GSP measurement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For the GSP measurement, subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes. Sixty minutes after- G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of GSP value.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.</intervention_name>
    <arm_group_label>GSP measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject must fulfill all of the following criteria to be eligible for the study:&#xD;
&#xD;
          1. Male or female with age between 20-80.&#xD;
&#xD;
          2. Ability and willingness to provide informed consent, adhere to the study visit&#xD;
             schedule and complete all study assessments and language specific questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following criteria will disqualify the subject from participation:&#xD;
&#xD;
          1. History of serious allergic reaction to galactose and have galactosemia.&#xD;
&#xD;
          2. History of receiving total gastrectomy, subtotal gastrectomy, celiac disease, or small&#xD;
             intestinal resection.&#xD;
&#xD;
          3. History of diabetes mellitus.&#xD;
&#xD;
          4. Subjects are children or handicapped people.&#xD;
&#xD;
          5. Subjects with any other reasons considered by the investigator not in the condition to&#xD;
             enter into the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Defense Medical Center, Taiwan</investigator_affiliation>
    <investigator_full_name>Tung Yuan Shih</investigator_full_name>
    <investigator_title>Research Assistant</investigator_title>
  </responsible_party>
  <keyword>GSP</keyword>
  <keyword>galactose single point (GSP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

